FY2027 Earnings Forecast for DVAX Issued By William Blair

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Equities researchers at William Blair issued their FY2027 earnings per share (EPS) estimates for Dynavax Technologies in a note issued to investors on Wednesday, June 4th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will earn $0.99 per share for the year. William Blair has a "Outperform" rating on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share.

DVAX has been the subject of a number of other research reports. The Goldman Sachs Group reduced their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research note on Thursday, April 17th. Wall Street Zen downgraded shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. JMP Securities lowered their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Dynavax Technologies currently has an average rating of "Hold" and an average target price of $24.00.

Dynavax Technologies Stock Performance

DVAX stock opened at $9.95 on Friday. The business has a 50 day moving average of $10.71 and a 200-day moving average of $12.25. The firm has a market cap of $1.19 billion, a PE ratio of 55.28 and a beta of 1.06. Dynavax Technologies has a 12-month low of $9.22 and a 12-month high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $68.16 million during the quarter, compared to analysts' expectations of $70.01 million.

Hedge Funds Weigh In On Dynavax Technologies

Several hedge funds have recently made changes to their positions in DVAX. Barclays PLC grew its holdings in Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after buying an additional 175,118 shares in the last quarter. KBC Group NV grew its stake in Dynavax Technologies by 68.7% during the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 2,857 shares in the last quarter. Entropy Technologies LP grew its stake in Dynavax Technologies by 17.2% during the fourth quarter. Entropy Technologies LP now owns 48,621 shares of the biopharmaceutical company's stock valued at $621,000 after acquiring an additional 7,121 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Dynavax Technologies during the 4th quarter worth approximately $71,000. Finally, Rhumbline Advisers lifted its stake in Dynavax Technologies by 4.7% in the 4th quarter. Rhumbline Advisers now owns 305,718 shares of the biopharmaceutical company's stock worth $3,904,000 after purchasing an additional 13,597 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.